Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ · Manufacturing · Pharmaceutical preparations
$2.64−$0.0500 (−1.86%) on the dayAs of the close; data may be delayed.
RCKT price, last 12 months
Key stats
- Previous close
- $2.69
- Open
- $2.71
- Day range
- $2.57 – $2.80
- 52-week range
- $2.53 – $5.45
- Volume
- 2.5M
- Avg volume (20 days)
- 1.8M
- Market cap
- $284.9M
Performance
1W−21.7%
1M−27.9%
3M−18.8%
6M−43.7%
YTD−24.8%
1Y−20.5%
vs S&P 500, 1Y−37.3 pts
Technicals and fundamentals
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $284.9M